Who are MP0420's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Penpulimab kcqx, Tevimbra, Loqtorzi, Unloxcyt, Jemperli, Libtayo.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mp0420.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

MP0420 — Competitive Intelligence Brief

MP0420 (MP0420) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor. Area: Oncology.

phase 3 PD-1 inhibitor PD-1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

MP0420 (MP0420) — National Institute of Allergy and Infectious Diseases (NIAID). MP0420 is a monoclonal antibody that targets and blocks PD-1 on T cells to enhance anti-tumor immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MP0420 TARGET	MP0420	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	PD-1 inhibitor	PD-1
Penpulimab kcqx	PENPULIMAB	Akeso Biopharma	marketed		Pd-1	2025-01-01
Tevimbra	TISLELIZUMAB	Beigene	marketed	Programmed Death Receptor-1 Blocking Antibody [EPC]	Pd-1	2025-01-01
Loqtorzi	TORIPALIMAB	Coherus Biosciences Inc	marketed	Programmed Death Receptor-1 Blocking Antibody [EPC]	Pd-1	2024-01-01
Unloxcyt	COSIBELIMAB	Checkpoint Therapeutics Inc	marketed	Programmed Death Ligand-1 Blocker [EPC]	Pd-1	2024-01-01
Jemperli	DOSTARLIMAB	GSK	marketed	Programmed Death Receptor-1 Blocking Antibody [EPC]	PD-1	2021-01-01
Libtayo	CEMIPLIMAB	Regeneron Pharmaceuticals	marketed		PD-1	2018-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor class)

Sun Yat-sen University · 11 drugs in this class
Bristol-Myers Squibb · 9 drugs in this class
Addpharma Inc. · 7 drugs in this class
Merck Sharp & Dohme LLC · 5 drugs in this class
Shanghai Henlius Biotech · 5 drugs in this class
Innovent Biologics (Suzhou) Co. Ltd. · 5 drugs in this class
Pfizer · 4 drugs in this class
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 4 drugs in this class
Amgen · 3 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MP0420 — Competitive Intelligence Brief. https://druglandscape.com/ci/mp0420. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab